Nanostics Inc. is a private Canadian company that develops and commercializes novel and noninvasive diagnostic tests. Its core technology, ClarityDX®, uses advanced machine learning algorithms to create a disease risk score that predicts the presence of diseases. ClarityDX is applicable to a wide range of cancers and other diseases. Nanostics’ lead product, ClarityDX Prostate®, is a test that improves the accuracy of detecting clinically significant prostate cancer. Read more at www.nanosticsdx.com. Follow Nanostics on LinkedIn, YouTube, Facebook, and Instagram.